ADX-914 + Placebo + ADX-914 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Safety Issues
Conditions
Safety Issues
Trial Timeline
Sep 8, 2020 → Jan 12, 2022
NCT ID
NCT04485481About ADX-914 + Placebo + ADX-914 + Placebo
ADX-914 + Placebo + ADX-914 + Placebo is a phase 1 stage product being developed by Q32 Bio for Safety Issues. The current trial status is completed. This product is registered under clinical trial identifier NCT04485481. Target conditions include Safety Issues.
What happened to similar drugs?
3 of 4 similar drugs in Safety Issues were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04485481 | Phase 1 | Completed |
Competing Products
20 competing products in Safety Issues